[Progress in new cardiovascular treatment. Background discussion and interview in the Basel Roche Research Center].
作者信息
Keil U
机构信息
Fortschritte der Medizin, Urban & Vogel GmbH, München.
出版信息
Fortschr Med. 1996 Feb 10;114(4):39-40.
PMID:8852686
Abstract
摘要
相似文献
1
[Progress in new cardiovascular treatment. Background discussion and interview in the Basel Roche Research Center].[心血管疾病新疗法的进展。巴塞尔罗氏研究中心的背景讨论与访谈]
Fortschr Med. 1996 Feb 10;114(4):39-40.
2
Mibefradil (posicor).
Compr Ther. 1997 Nov;23(11):761-3.
3
[Induction of bradycardia by mibefradil in antihypertensive combination therapy].
Dtsch Med Wochenschr. 1998 Apr 24;123(17):547.
4
Mibefradil withdrawn from the market.
Ann Pharmacother. 1998 Jul-Aug;32(7-8):841. doi: 10.1345/aph.17356.
5
Case report: rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin.
J Clin Pharmacol. 1999 Mar;39(3):310-2.
6
Good news for experimental concept but bad news for clinically effective therapy.
Circulation. 1999 Jan 19;99(2):198-200. doi: 10.1161/01.cir.99.2.198.
7
Rhabdomyolysis due to interaction of simvastatin with mibefradil.辛伐他汀与米贝拉地尔相互作用导致的横纹肌溶解症。
Lancet. 1998 Jun 27;351(9120):1929-30. doi: 10.1016/S0140-6736(05)78613-X.
8
[Treatment of myocardial ischemia with reference to blood pressure values].
Cardiology. 1993;82 Suppl 2:58-65. doi: 10.1159/000175918.
9
Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure.选择性T通道钙拮抗剂米贝拉地尔长期治疗心力衰竭可提高生存率。
J Am Coll Cardiol. 1997 Feb;29(2):416-21. doi: 10.1016/s0735-1097(96)00491-3.
10
[Current therapy of coronary heart disease. Conservative measures].[冠心病的当前治疗方法。保守措施]
Internist (Berl). 1998 Sep;39(9):1001-2.
Zotero 插件